India must prioritize including the typhoid conjugate vaccine in its immunization program to combat the disease's high burden ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

Ajinomoto Co., Inc. has signed a licensing agreement with Astellas Pharma Inc. for the use of AJICAP—an antibody-drug conjugate (ADC) development and manufacturing technology—as part of its CDMO ...

Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the ...

NetTargets employs an AI system that combines multi-omics data with neural network modelling for drug discovery.

EMA grants Orphan Drug Designation to GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 to treat pulmonary neuroendocrine carcinoma: London, UK Wednesday, October 29, 2025 ...

The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action —— Lead ...

October 2025 proved to be a significant month for the oncology landscape, marked by a wave of key regulatory decisions from the US FDA. This period saw important full and accelerated drug approvals ...

Inventprise, a Redmond, Wash.–based biotechnology company developing vaccines for infectious diseases, is laying off ...